NCT03955380View on ClinicalTrials.gov

MAD Phase I Study to Investigate Contraloid Acetate

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

April 3, 2019

Study Completion Date

April 3, 2019

Conditions
Alzheimer DementiaAlzheimer Disease
Interventions
DRUG

Contraloid

Oral administration of capsules, drug substance or placebo without any exipients.

Trial Locations (1)

52425

Forschungszentrum Jülich, Jülich

Sponsors

Collaborators (1)

NeuroScios, Austria
All Listed Sponsors
collaborator

Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany

UNKNOWN

collaborator

Medical University of Vienna

OTHER

collaborator

NeuroScios, Austria

UNKNOWN

collaborator

Nuvisan, Germany

UNKNOWN

collaborator

Fundación Teófilo Hernando, Spain

OTHER

collaborator

Alzheimer's Association

OTHER

lead

Prof. Dr. Dieter Willbold

OTHER

NCT03955380 - MAD Phase I Study to Investigate Contraloid Acetate | Biotech Hunter | Biotech Hunter